Clinical trials: Pancreas Tumor
Pancreatic Cancer
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who…
- Trial name
- NCT07589569
- Testing
- HRS-7058
- Where
- 2 sites in China
- Volunteers
- 92 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Radiation Therapy, Cancer
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Collect blood samples and associated clinical data prior to, during, and post radiation treatment.
- Conditions
- Radiation Therapy, Cancer, Cancer of Anus, Cancer of Bladder
- Trial name
- RADIANT (NCT03133286)
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- DxTerity Diagnostics
Pancreatic Cancer
QUILT-3.080: NANT Pancreatic Cancer Vaccine
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.
- Trial name
- NCT03586869
- Testing
- Aldoxorubicin HCl, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ImmunityBio, Inc.
Brain Cancer, Cancer
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
The Radiotracer 18F-FLT can non-invasively assess excessive cell growth in PET scan images. Tumour growth rate is a useful indicator of tumour aggression and response to treatment.
- Conditions
- Brain Cancer, Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT01065805
- Testing
- 18F-FLT
- Where
- Canada
- Volunteers
- 94 people
- Sponsor
- AHS Cancer Control Alberta
HCC - Hepatocellular Carcinoma, Cholangiocarcinoma
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively.
- Conditions
- HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT07106827
- Testing
- GV20-0251
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Neoplasms, Pancreatic
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis.
- Trial name
- NCT03681951
- Testing
- GSK3145095, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Expanded Access in Pancreatic Cancer
Expanded Access RBS2418 Treatment
This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.
- Trial name
- NCT05683470
- Testing
- RBS2418
- Sponsor
- Riboscience, LLC.
Locally Advanced or Metastatic Solid Tumours
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT04999969
- Testing
- AZD0171, Durvalumab, Gemcitabine
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line treatment in patients with unresectable locally…
- Trial name
- NCT06313970
- Testing
- QL1706, Nab-paclitaxel, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Trial name
- NCT00987766
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pancreatic Cancer
Vaccine Treatment for Surgically Resected Pancreatic Cancer
This 2-phase study will determine the safety of treating patients with pancreatic cancer with the genetically engineered HyperAcute-Pancreatic cancer vaccine.
- Trial name
- NCT00255827
- Testing
- HyperAcute-Pancreatic Cancer Vaccine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- NewLink Genetics Corporation
Pancreatic Cancer
Covid-19 Pandemic and Pancreatic Surgery in Italy
Pancreatic cancer (PC) is recognized as one of the most challenging tumors to deal with and it is still characterized by a poor long-term prognosis.
- Trial name
- PanCOVID (NCT04380766)
- Testing
- Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer
- Where
- Italy
- Volunteers
- 730 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuroendocrine Tumors, Carcinoid Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied.
- Trial name
- NCT01253161
- Testing
- Pasireotide Long Acting Release (LAR)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Cancer, Liver Cancer
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
The preclinical data have demonstrated the feasibility of fluorescence-guided tumor resection by the Cancer Vision Googles (CVG) with LS301 in animal models.
- Conditions
- Pancreatic Cancer, Liver Cancer, Gastric Cancer, Gastrointestinal Stromal Cancer
- Trial name
- NCT04105062
- Testing
- LS301, Cancer Vision Goggles
- Sponsor
- Washington University School of Medicine
Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
This phase I trial studies the highest and safest doses of dovitinib lactate, paclitaxel albumin-stabilized nanoparticle formulation, and gemcitabine hydrochloride when given together.
- Conditions
- Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT02048943
- Testing
- dovitinib lactate, gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Pancreatic Cancer
Silicon Microsieve Device vs Cell Surface Marker-based Platform for the Isolation of Pancreatic Cancer CTCs
The study aims to compare the use of a microsieve device vs a cell surface marker-based platform for the isolation of pancreatic cancer circulating tumor cells
- Trial name
- NCT04638868
- Testing
- Microsieve device, Cell surface marker-based platform
- Volunteers
- 26 people
- Sponsor
- Singapore General Hospital
Pancreatic Cancer
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.
- Trial name
- NCT05911217
- Testing
- CT041 autologous CAR T-cell injection
- Where
- 8 sites in China
- Volunteers
- 20 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Pancreatic Carcinoma, Biliary Obstruction
Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction
The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with pancreatic carcinoma and biliary obstruction who are treated by stent insertion with or without high-intensity…
- Trial name
- HIFU (NCT03962478)
- Testing
- biliary stent and high-intensity focused ultrasound ablation system, biliary stent
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Xuzhou Central Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.